Andrew Dean
Overview
Explore the profile of Andrew Dean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
3058
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan A, McSweeney T, Sikotra N, Adler B, van Hagen T, Summers Q, et al.
Immunotherapy
. 2025 Feb;
17(2):103-111.
PMID: 39995195
Aim: We describe a single-center burden of admissions for irAE management and rechallenge feasibility. Methods: A retrospective single-center study of patients receiving immunotherapy between 2015-2018 assessing irAE and immunotherapy rechallenge...
2.
Wainberg Z, Melisi D, Macarulla T, Pazo Cid R, Chandana S, De La Fouchardiere C, et al.
Future Oncol
. 2025 Feb;
21(7):765-774.
PMID: 39935331
No abstract available.
3.
Zhang B, He P, Lawrence J, Wang S, Tuck E, Williams B, et al.
Nature
. 2023 Dec;
635(8039):668-678.
PMID: 38057666
Human limbs emerge during the fourth post-conception week as mesenchymal buds, which develop into fully formed limbs over the subsequent months. This process is orchestrated by numerous temporally and spatially...
4.
Talbot A, Talbot T, Shaughnessy E, Glass A, Das A, Watanabe Y, et al.
J Gastrointest Oncol
. 2023 Nov;
14(5):2221-2228.
PMID: 37969823
Background: Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of approximately 10.7% in Australia. It is becoming an increasingly common cause of cancer mortality. The therapeutic model for PDAC...
5.
Wainberg Z, Melisi D, Macarulla T, Pazo Cid R, Chandana S, De La Fouchardiere C, et al.
Lancet
. 2023 Sep;
402(10409):1272-1281.
PMID: 37708904
Background: Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine...
6.
Matulonis U, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, et al.
J Clin Oncol
. 2023 Aug;
41(29):4705-4706.
PMID: 37535884
No abstract available.
7.
Matulonis U, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, et al.
J Clin Oncol
. 2023 Jan;
41(13):2436-2445.
PMID: 36716407
Purpose: Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα). SORAYA...
8.
Taplin S, Andrews-Jones B, Chainey A, Das S, Dawson D, Dean A, et al.
Future Healthc J
. 2022 Dec;
9(3):321-325.
PMID: 36561817
Introduction: The COVID-19 vaccination service is a key component in the UK approach to reducing disease morbidity and mortality. Groups within the population at increased risk of severe outcomes from...
9.
Tempero M, Pelzer U, OReilly E, Winter J, Oh D, Li C, et al.
J Clin Oncol
. 2022 Dec;
41(11):2007-2019.
PMID: 36521097
Purpose: This randomized, open-label trial compared the efficacy and safety of adjuvant -paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430). Methods: We assigned...
10.
OMalley D, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al.
Gynecol Oncol
. 2022 Oct;
167(3):404-413.
PMID: 36273926
Objective: ARIEL3 (NCT01968213) is a placebo-controlled randomized trial of the poly(ADP-ribose) polymerase inhibitor rucaparib as maintenance treatment in patients with recurrent high-grade ovarian carcinoma who responded to their latest line...